BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nanobiotix readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nanobiotix's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04892173-2634@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:NBTXR3: Phase 3 readout est. (NCT04892173)
DESCRIPTION:NBTXR3\, phase 3.\nStudy: JNJ-90301900 (NBTXR3) Activated by Ra
 diotherapy With or Without Cetuximab in LA-HNSCC\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 btxr3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04892173
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667908-2634@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:NBTXR3: Phase 2 readout est. (NCT06667908)
DESCRIPTION:NBTXR3\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidati
 on Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nbtxr3#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06667908
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
